O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

May 26, 2023

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

May 25, 2023

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

May 22, 2023

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

May 18, 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

May 15, 2023

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

May 15, 2023

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

May 12, 2023

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

May 11, 2023

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

May 08, 2023

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

May 05, 2023

Devika Das, MD, MSHQS,discusses updated data on the use of immunotherapy and platinum-based chemotherapy regimens in extensive-stage small cell lung cancer.

April 26, 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

April 26, 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

April 19, 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

April 19, 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

April 12, 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

April 12, 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

April 05, 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

April 05, 2023

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

March 29, 2023

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

March 29, 2023

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.